Supernus Pharmaceuticals Inc’s recently made public that its SVP, Chief Medical Officer Rubin Jonathan unloaded Company’s shares for reported $36292.0 on Feb 21 ’25. In the deal valued at $39.15 per share,927 shares were sold. As a result of this transaction, Rubin Jonathan now holds 7,853 shares worth roughly $0.25 million.
Then, Bhatt Padmanabh P. sold 9,477 shares, generating $376,237 in total proceeds. Upon selling the shares at $39.70, the Sr. VP of IP, CSO now owns 10,149 shares.
Before that, Bhatt Padmanabh P. sold 2,573 shares. Supernus Pharmaceuticals Inc shares valued at $101,942 were divested by the Sr. VP of IP, CSO at a price of $39.62 per share. As a result of the transaction, Bhatt Padmanabh P. now holds 10,149 shares, worth roughly $0.33 million.
Cantor Fitzgerald downgraded its Supernus Pharmaceuticals Inc [SUPN] rating to a Neutral from a an Overweight in a research note published on February 19, 2025; the price target was decreased to $36 from $57. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Piper Sandler also remained covering SUPN and has decreased its forecast on September 11, 2024 with a “Neutral” recommendation from previously “an Overweight” rating.
Price Performance Review of SUPN
On Tuesday, Supernus Pharmaceuticals Inc [NASDAQ:SUPN] saw its stock fall -0.45% to $32.33. Over the last five days, the stock has lost -2.81%. Supernus Pharmaceuticals Inc shares have fallen nearly -10.61% since the year began. Nevertheless, the stocks have risen 21.71% over the past one year. While a 52-week high of $40.28 was reached on 02/05/25, a 52-week low of $25.55 was recorded on 05/07/25.
Levels Of Support And Resistance For SUPN Stock
The 24-hour chart illustrates a support level at 31.56, which if violated will result in even more drops to 30.80. On the upside, there is a resistance level at 33.09. A further resistance level may holdings at 33.85.
